1. Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model. (5th October 2020) Authors: Rodrigo, M. J.; Cardiel, M. J.; Fraile, J. M.; Mendez-Martinez, S.; Martinez-Rincon, T.; Subias, M.; Polo, V.; Ruberte, J.; Ramirez, T.; Vispe, E.; Luna, C.; Mayoral, J. A.; Garcia-Martin, E. Journal: Biomaterials science Issue: Volume 8:Number 22(2020) Page Start: 6246 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗